Literature DB >> 1568710

Hepatitis B virus DNA in chronic HBsAg carriers: correlation with HBeAg/anti-HBe status, anti-HD and liver histology.

T Stroffolini1, E Sagnelli, M Rapicetta, F M Felaco, P Filippini, T Annella, A Petruzziello, P Chionne, B Sarrecchia, F Piccinino.   

Abstract

Hepatitis B virus DNA was determined in the sera of 198 chronic hepatitis B surface antigen (HBsAg) carriers by the spot hybridization technique. The results were correlated with hepatitis Be antigen (HBeAg) and antibody (anti-HBe), delta antibody (anti-HD) and liver histology. All subjects had a liver biopsy. The prevalence of HBV DNA was 63% in HBeAg-positive subjects and 8.8% in anti-HBe positives. HBV DNA was not found more frequently in chronic HBsAg carriers who had histological evidence of liver disease than in carriers without such evidence. Anti-HD was detected in 48.5% of subjects, with an increasing trend (p less than 0.001) according to the severity of liver disease. Among patients with more severe liver disease (CAH and cirrhosis), HBV DNA and HBeAg were detected less frequently in anti-HD-positive than in anti-HD-negative subjects (7% vs. 42.3%, p less than 0.001 and 7% vs. 34.4%, p less than 0.005, respectively). These findings indicate that HDV infection jointly affects both HBeAg status and HBV DNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568710

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.

Authors:  Ya-Fei Guo; Jing-Xin Pan; Wei-Huang Zhuang
Journal:  Infect Agent Cancer       Date:  2018-12-12       Impact factor: 2.965

2.  Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients.

Authors:  Weiyang Li; Xiaofang Cui; Qing Huo; Yanwei Qi; Yuhui Sun; Meihua Tan; Qingsheng Kong
Journal:  Curr Genomics       Date:  2019-01       Impact factor: 2.236

3.  Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.

Authors:  Arnolfo Petruzziello; Rocco Sabatino; Giovanna Loquercio; Annunziata Guzzo; Lucia Di Capua; Francesco Labonia; Anna Cozzolino; Rosa Azzaro; Gerardo Botti
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

4.  Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.

Authors:  Chau Le Ngoc; Thanh Tran Thi Thanh; Phuong Tran Thi Lan; Trinh Nguyen Mai; Trang Nguyen Hoa; Ngoc Nghiem My; Tan Le Van; Hung Le Manh; Phuong Le Thanh; Chau Nguyen Van Vinh; Guy Thwaites; Graham Cooke; Gabrielle M Heilek; Cecilia Shikuma; Thuy Le; Stephen Baker; Motiur Rahman
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

5.  Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review.

Authors:  Arnolfo Petruzziello; Giovanna Loquercio; Rocco Sabatino; Daniel Vasile Balaban; Najeeb Ullah Khan; Mauro Piccirillo; Luis Rodrigo; Lucia di Capua; Annunziata Guzzo; Francesco Labonia; Gerardo Botti
Journal:  J Clin Lab Anal       Date:  2019-03-07       Impact factor: 2.352

6.  Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B.

Authors:  Wenbiao Chen; Chenhong Lin; Lan Gong; Jianing Chen; Yan Liang; Ping Zeng; Hongyan Diao
Journal:  Curr Genomics       Date:  2019-05       Impact factor: 2.236

Review 7.  Hepatitis delta virus and hepatocellular carcinoma: an update.

Authors:  Raffaella Romeo; Arnolfo Petruzziello; Eve Isabel Pecheur; Floriana Facchetti; Riccardo Perbellini; Enrico Galmozzi; Najeeb Ullah Khan; Lucia Di Capua; Rocco Sabatino; Gerardo Botti; Giovanna Loquercio
Journal:  Epidemiol Infect       Date:  2018-07-11       Impact factor: 4.434

8.  Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis.

Authors:  Ping Zhang; Qingli Liu; Mei Yuan; Lina Wang
Journal:  Infect Agent Cancer       Date:  2018-08-29       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.